Navigation Links
Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea
Date:8/5/2010

MALVERN, Pa., Aug. 5 /PRNewswire/ -- Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced positive results today from a pharmacodynamic and pharmacokinetic clinical trial of the Company's lead product V-101, a topical cream under investigation for the treatment of erythema in patients with rosacea.

The double-blinded, placebo-controlled, crossover clinical trial of 22 patients with rosacea was designed to evaluate the bioavailability of V-101 and provide preliminary evidence of efficacy as measured by improvement in moderate to severe erythema, the bright redness of the skin associated with rosacea.  V-101 had a side effect profile similar to placebo and V-101's active ingredient was not detectable in study participants' plasma, a strong indication of the product's overall tolerability and safety profile.  Additionally, the study results were positive for all endpoints, demonstrating a clinically and statistically significant improvement in treating the erythema associated with rosacea.

"This important study demonstrated that V-101 has a good safety profile and provides statistically significant evidence of effectiveness in treating the erythema of rosacea," said Dr. Neal Walker, president and chief executive officer of Vicept. "We look forward to advancing our clinical program into Phase II and continuing our efforts to develop this product for the 16 million people in the United States who live with this common, chronic skin condition every day."

"Rosacea is devastating to people who live with it and the primary complaint is erythema, the red sunburn appearance that accompanies the disease," said James Leyden, M.D., Professor E
'/>"/>

SOURCE Vicept Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
2. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
3. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
4. Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results
5. Talecris Biotherapeutics Announces Premerger HSR Filing
6. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
7. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
10. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
11. Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... June 17, 2013 zuChem Inc., ... health and nutrition, announced today that the United ... 2 patents - US 8,367,346 entitled “Methods for ... entitled "Process for producing D-Mannitol." These two patents ... of natural food sweetener products from abundant, renewable ...
(Date:6/17/2013)... June 17, 2013 Cedars-Sinai Medical Center, ... the country, recovered more than $300 million by ... of OnBase, Hyland Software,s enterprise content management ... provide a common revenue cycle management platform to ... were in place for both hospital and physician ...
(Date:6/17/2013)... COLUMBUS, Ohio , June 17, 2013 /PRNewswire/ ... has raised an additional $2.5 million from Radius ... $11.5 million. The Series B originally raised $9 ... with participation by existing investor, Charter Life Sciences. ... system is the first and only product that ...
(Date:6/17/2013)... , June 17, 2013 /PRNewswire-iReach/ -- The Greater ... Riedford , President/Founder of Riedford Management, Inc. to its Board ... a member of the Chamber,s Board of Advisors," said ... is one of the most prestigious positions to hold in ... experience our new board members will contribute." The ...
Breaking Biology Technology:zuChem Receives Two Polyol Patents 2Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase 2Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase 3Minimally Invasive Devices Adds $2.5 Million to its Series B 2Raleigh Chamber Names Bob Riedford to Board of Advisors 2
... Graduate Institute,(KGI) in collaboration with City of Hope, ... launch of its new Certificate in Bioscience,Management program ... funding to allow a limited number of City ... scholarships that will cover tuition., "KGI has ...
... ALTO, Calif., Aug. 14 CV Therapeutics,Inc. (Nasdaq: ... from the,European Medicines Agency (EMEA) for the brand name ... announced that the EMEA had granted,marketing authorization for ranolazine ... brand name Latixa., "Securing approval for the Ranexa ...
... Eric P. Loukas, Industry Veteran, Named as CEO ... Co-Founder, Named as President and COO, ALTAMONTE SPRINGS, ... specialty biotechnology company focused on,in-licensing and commercialization of niche ... as Chief Executive Officer,effective August 12, 2008. Current President, ...
Cached Biology Technology:City of Hope Helps KGI Launch New Management Training Program for Scientists 2City of Hope Helps KGI Launch New Management Training Program for Scientists 3CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) 2Milestone Biosciences, LLC Further Strengthens Executive Management Team 2
(Date:6/17/2013)... by fungi, bacteria, and algae, is a common component ... used in the medical field it,s approved by ... fluids and used during surgery as a substance that ... other drugs. , Now Profs. Ehud Gazit and Daniel ... and Biotechnology and the Sagol School of Neuroscience, along ...
(Date:6/17/2013)... will be the topics under discussion during the ... the third consecutive year, this will be a ... experiences among members of Academy, Business, Educators, Entrepreneurs, ... speakers: Elisa Martn Garijo (IBM South Europe), Chris ... Mary O,Donovan (Hovione), among others. E3 Forum - ...
(Date:6/17/2013)... available in French . ... older mice with Alzheimer,s disease can be reversed with treatment. ... Hospital - The Neuro, at McGill University and at Universit ... receptor in the brain of mice with advanced Alzheimer,s disease ... the Journal of Neuroinflammation in May, also suggest ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... Gasterosteus aculeatus , is one of the most thoroughly ... particularly useful model for understanding variation in physiology, behavior, ... in the wild. On biological levels from molecular ... with the population level, it has proven far more ...
... a little gooey, but it,s not turning mums, brains into ... University. The study conducted by the Centre for ... fears mothers may have that pregnancy affects their cognitive functions, ... findings have been released as part of Mental Health Week, ...
... ability to respond? Biodiversity in a Warmer World, published ... Science , illustrates that cross-disciplinary research fostered by ... this urgent debate. , As an extremely diverse region ... the most to lose as a result of global ...
Cached Biology News:Fitness in a changing world 2Fitness in a changing world 3Pregnancy not turning minds to mush: Study 2Smithsonian perspective: Biodiversity in a warmer world 2
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... analysis standard is a lyophilized mixture ... alcohol; molecular weights range from 152 ... for use with the Aminex HPX-87C ... for column testing or semiquantitative determination. ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... The kit was tested on rat tissue ... a yeast ( S. cerevisae ) extract. It ... rat tissues and cell lines. Application: A simple ... sub-cellular fractions based on the detection of the ...
Biology Products: